Study S000977

Impact of Additional Treatment With Empagliflozin or Semaglutide on Endothelial Function and Other Clinical Parameters and Biomarkers in T1DM Patients

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT05857085
Acronym: ENDIS
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 90
Start: 2021-12-15
Primary completion: 2022-03-10
Lead sponsor: General and Teaching Hospital Celje
Conditions: Endothelial Dysfunction; Diabetes Mellitus, Type 1; Biomarkers; Endothelial Progenitor Cells; SGLT 2 Inhibitors; Incretins; Glucose Excursions; FMD; FPF; Arterial Stiffness
Interventions: DRUG:Semaglutide Pen Injector [Ozempic]; DRUG:Empagliflozin 10 MG
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

evaluation of endothelial function by flow mediated dilation (FMD) of brachial artery [12 weeks]
evaluation of endothelial function by strain gauge plethysmography as change in forearm blood flow [12 weeks]
evaluation of arterial stiffness with peak wave velocity ( PWV) [12 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.